Browse Conditions Browse Medicines

NICE recommend tildrakizumab (Ilumetri▼) for the treatment of moderate to severe plaque psoriasis

Ilumetri▼, for Nummular psoriasis and Psoriasis

The National Institute for Health and Care Excellence (NICE) has approved Almirall's psoriasis treatment tildrakizumab, brand name Ilumetri ▼ for use by the NHS in England and Wales.

The full recommendation states that:

Tildrakizumab (Ilumetri) is available on the NHS as a possible treatment for plaque psoriasis in adults if:
  • the psoriasis is severe and affects quality of life and
  • the psoriasis has not improved with other treatments, for example, ciclosporin, methotrexate and phototherapy, or these can’t be taken.
Tildrakizumab may be stopped between 12 and 28 weeks of starting treatment, but should be stopped at 28 weeks if the psoriasis does not improve enough.

When assessing how psoriasis affects your quality of life, healthcare professionals should take into account any disabilities or difficulties in communicating you might have.

If you are not eligible for tildrakizumab but are already taking it, you should be able to continue until you and your doctor decide when best to stop.

You can follow developments with this medicine using our Medicines Tracker service which provides users with updates about the medicines they are interested in, including updates to Patient Leaflets, information from medicine regulators and clinical trial information. To track information about this medicine please click on this article and follow the 'About this medicine' link then select 'Follow medicine'.


Psoriasis treatment pathway. NICE

About Ilumetri
Ilumetri is a medicine that acts on the immune system and is used to treat plaque psoriasis, a disease causing red, scaly patches on the skin. It is used in adults with moderate to severe disease for whom treatments applied to the skin are not suitable.

The active substance in Ilumetri, tildrakizumab, is a monoclonal antibody (a type of protein) which is designed to attach to interleukin 23 and block its activity. Interleukin 23 is a substance that controls the growth and maturation of some types of T cells. These T cells, which are part of the immune system (the body's natural defences), are involved in causing inflammation that is linked to the development of plaque psoriasis. By blocking the action of interleukin 23, Ilumetri reduces inflammation and symptoms associated with the disease.

Ilumetri was first made available in the EU in 2018. It is manufactured by Almirall.

European Medicines Agency website page for Ilumetri
Accessed 24/04/19
Links available in full article

© NICE [2019] Tildrakizumab for treating moderate to severe plaque psoriasis Available from: See Link below. All rights reserved. Subject to Notice of rights
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

The information provided by NICE was accurate at the time this article was issued.

Tildrakizumab for treating moderate to severe plaque psoriasis

New medicines and vaccines that are under additional monitoring have an inverted black triangle symbol (▼) displayed in their package leaflet and summary of product characteristics, together with a short sentence explaining what the triangle means – it does not mean the medicine is unsafe. You should report all suspected adverse drug reactions (ADRs) for these products. ADRs can be reported by your doctor, pharmacist or online via the Yellow Card system.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions (side effects) after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals or patients are asked to report any suspected adverse reactions via the Yellow Card Scheme at or search for MHRA Yellow Card in the Google Play or Apple App Store.

Disclaimer: This site is designed to offer information for general educational purposes only. The health information furnished on this site and the interactive responses are not intended to be professional advice and are not intended to replace personal consultation with a qualified physician, pharmacist, or other healthcare professional. We cannot provide individual medical advice. You must always seek the advice of a professional for questions related to a disease, disease symptoms, and appropriate therapeutic treatments.

About Nummular psoriasis About Psoriasis About medicine